Hemostatic powder for gastrointestinal malignant tumor bleeding

Area of Science:

• Gastroenterology and Endoscopy
• Oncology
• Biomaterials

Background:

• Malignant gastrointestinal (GI) bleeding presents unique challenges due to diffuse oozing and friable tissues.
• Conventional endoscopic treatments have limitations, leading to low hemostasis rates and high rebleeding risks.
• Endoscopic hemostasis is crucial for bridging patients to definitive oncological therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of hemostatic powders as a treatment for malignant GI bleeding.
• To explore the potential of novel hemostatic powder agents beyond existing options.
• To assess hemostatic powders as a frontline endoscopic approach.

Main Methods:

• Review of randomized controlled trials and meta-analyses comparing hemostatic powders to conventional endoscopic therapy.
• Focus on agents providing broad mucosal coverage via non-contact application.
• Analysis of safety data, including luminal and systemic adverse events.

Main Results:

• Hemostatic powders demonstrate superior immediate hemostasis rates.
• Lower rebleeding rates are observed with hemostatic powder agents compared to conventional methods.
• No luminal or systemic adverse events have been reported in studies of hemostatic powders for malignant bleeding.

Conclusions:

• Hemostatic powders represent a significant advancement in managing malignant GI bleeding.
• These agents offer a safe and effective endoscopic solution, improving patient outcomes.
• Further exploration of various hemostatic powder agents is warranted.